

Research Article**Analysis of role of plasma obestatin levels in obesity
associated with daily life style****Asghar Ali¹, Muhammad Shaharyar Afzal²
and Farah Asghar³**¹AmnaInayat medical college Sheikhpura, Pakistan²Medical Officer at THQ hospital Wazirabad Gujranwala, Pakistan.³Khawaja Muhammad Safdar medical college Sialkot, Pakistan**Corresponding author:** DrAsghar Ali, AmnaInayat Medical College, Sheikhpura, Pakistan**Tel:** 0092-343-4556007. **E-mail:** dr.aapowar@gmail.com

Source(s) of support in the form of grants, equipment, drugs, or all of the above: None.

Conflict of interest: None

ABSTRACT

Introduction: Obesity is a pathological condition, which results from an imbalance between caloric intake and expenditure, and is characterized by excessive body fat accumulation, that has severe impact on life quality and life expectance due to the burden of associated co-morbidities. **Aims of the study:** The main aim of the present study is to analyze the role of plasma obestatin levels in obesity which is associated with daily life style. **Methodology of the study:** This study was conducted according to the rules and regulations of ethical committee of the hospital. The data was collected from 50 obese patients which was also suffering from heart and cholesterol diseases. These patients who come at AmnaInyat medical college hospital and THQ hospital Wazirabad were selected for this study during Jan 2017 to May 2017. **Results:** Mean fasting obestatin levels was 0.450 ± 0.468 and 0.959 ± 0.889 respectively in normal and obese and the difference of mean fasting obestatin levels between the both groups was statistically significant with p value 0.000. **Conclusion:** Obestatin plays very important role in obesity and it is directly correlated with blood glucose level.

Key words: Obestatin, obesity, diseases, patients.**INTRODUCTION**

Obesity is a pathological condition, which results from an imbalance between caloric intake and expenditure, and is characterized by excessive body fat accumulation, that has severe impact on life quality and life expectance due to the burden of associated co-morbidities. Recent data from the World Health Organization suggest that 11% of the world population (more than half a billion people) is obese, while 35% is overweight¹. Furthermore, the prevalence of obesity is continuously increasing worldwide, so revealing the patho mechanism and finding effective

treatments have become urgent and essential. During the past decades much research has highlighted that neurotransmitter systems controlling appetite and feeding behavior, cognitive function, stress and reward behavior are strongly and reciprocally connected². Food intake is normally regulated by a homeostatic drive to restore energy balance, while in certain conditions hedonic or reward-based regulation favors the consumption of highly palatable, energy-dense foods³.

Obestatin is a 23-acid metabolic peptide, derived from the preproghrelin gene which was isolated first from the rat stomach in 2005⁴. However, obestatin is also expressed in other GI organs (pancreas, liver), adipose tissue, skeletal muscle, lungs, thyroid and mammary glands and testes, suggesting a multifunctional role of it, which can act both centrally and peripherally⁵. It was originally described as a direct antagonist of ghrelin with anorexigenic effect. Both central and peripheral injection decreased food intake in a time and dose-dependent manner, body weight gain, and intestinal motility via the G-protein coupled receptor 39 (GPR39) a member of the GHSR family which was rapidly refuted as a receptor for obestatin by several studies⁶. To note, recent data suggest that obestatin may act through the GPR39 receptor in an autocrine/paracrine manner peripherally, namely as mitogenic factor in myoblasts and GPR39 could mediate the metabolic effects of obestatin in the adipose tissue and GI system⁷.

In addition, obestatin has been shown to be positively correlated with ghrelin. This suggests that levels of both obestatin and ghrelin may be altered in obesity and insulin resistance. Obestatin has been reported to decrease vascular cell adhesion molecule-1 expression in endothelial cells when stimulated with tumour necrosis factor- α , and to increase oxidized low-density lipoprotein binding to macrophages. Therefore, it may also have a potential function in the regulation of blood pressure⁸.

Aims of the study

The main aim of the present study is to analyze the role of plasma obestatin levels in obesity which is associated with daily life style.

Methodology of the study

This study was conducted according to the rules and regulations of ethical committee of the hospital. The data was collected from 50 obese patients which was also suffering from heart and cholesterol diseases. These patients who come at AmnaInyat medical college hospital and THQ hospital Wazirabad were selected for this study during Jan 2017 to May 2017. Demographic factors were also asked to the student. Body mass index (BMI) and waist circumference (WC) were done for patients and controls as anthropometrical tests, while fasting serum glucose (FSG) measured using spectrophotometric technique. Each serum sample was analyzed for obestatin hormone and fasting insulin using enzyme linked immune sorbent assay (ELISA).

Statistical analysis

SPSS analysis test was used in making a comparison of the two-tailed P value of the two groups with a significance set at $p < 0.05$. Results were considered to be of statistical significance if the two-tailed p-value was less than 0.05.

RESULTS

Mean fasting obestatin levels was 0.450 ± 0.468 and 0.959 ± 0.889 respectively in hypertensive and normotensive obese and the difference of mean fasting obestatin levels between the both groups was statistically significant with p value 0.000.

Table 01: Comparison of mean fasting obestatin levels between hypertensive and normotensive obese

Group	n	Mean	Std. Deviation	P Value
Hypertensive obese	57	0.450	0.468	0.000
Normotensive obese	57	0.959	0.889	

Table 02: Comparison of mean fasting blood cholesterol levels between normal and obese patients

Group	n	Mean	Std. Deviation	P Value
Normal	57	206.42	44.420	0.644
Obese patients	57	202.39	48.344	

Mean fasting blood cholesterol level was 206.42 ± 44.420 and 202.39 ± 48.344 respectively in normal and obese and the difference was not statistically significant with p value 0.644.

DISCUSSION

Hormones and neuropeptides control and integrate the neurocircuits of metabolism, thirst, thermoregulation, and sleep overlapping in the hypothalamus. Accordingly, besides its peripheral effects, central actions of obestatin were also identified⁹. To note first, when administered ICV this peptide inhibited thirst in fed and fasted male rats, and pretreatment with obestatin also neutralized the dipsogenic effect of angiotensin II. Furthermore, it was also suggested that the anorexigenic effect of this peptide is a consequence of the thirst inhibition, the so called dehydration anorexia¹⁰.

The neurogenesis in the adult hippocampus involves the proliferation, migration and differentiation of progenitor cells. These processes are impaired by different conditions, such as hypoxia, addictive drugs, sustained exposure to stress among others, while certain hormones and growth factors promote the proliferation and survival of the hippocampal neurons¹¹.

Obesity has become a major public health problem throughout the world and at least one-third of Arabs are obese, and this figure is rising steadily despite increased interest in fitness. Excess fat accumulation promotes the development of insulin resistance, glucose intolerance and type 2 diabetes mellitus¹⁻⁵. The increasing prevalence of obesity is a serious health concern. Obesity is known to be strongly associated with hypertension and other arteriosclerotic disease, but the pathogenic mechanisms linking hypertension and obesity have not been fully determined. The possible roles of obestatin and ghrelin in obesity and metabolic syndrome have been studied. Changes in the concentrations of these hormones, and in the ghrelin/obestatin ratio, may be risk factors for obesity and hypertension¹¹.

Obestatin levels were significantly reduced suggesting that the secretion of the Ghrelin and Obestatin is regulated in an opposing manner by the nutritional status. These findings suggest that obestatin could modulate endogenous

Ghrelin actions, and have shown that obestatin may inhibit jejunal activity and may suppress gastric emptying activity¹².

The role of obestatin in BP regulation and insulin sensitivity is unclear, but systolic BP has been shown to be an independent predictor of the ghrelin/obestatin ratio. In addition, fasting plasma concentrations of obestatin are reduced in insulin resistance and are positively associated with whole-body insulin sensitivity in nondiabetic humans¹³. In the present study, obese patients had lower fasting plasma obestatin concentrations than controls.

CONCLUSION

Obestatin plays a very important role in obesity and it is directly correlated with blood glucose level. Furthermore, there was a clear relationship between obestatin and both BP and HOMA-IR, suggesting that obestatin might play a role in BP regulation.

REFERENCES

1. Rhéaume, C, Leblanc, MÈ, Poirier, P. Adiposity assessment: explaining the association between obesity, hypertension and stroke. *Expert Rev Cardiovasc Ther* 2011; 9: 1557–1564.
2. Berthold, HK, Giannakidou, E, Krone, W. Influence of ghrelin gene polymorphisms on hypertension and atherosclerotic disease. *Hypertens Res* 2010; 33: 155–160.
3. Gurriarán-Rodríguez, U, Al-Massadi, O, Roca-Rivada, A. Obestatin as a regulator of adipocyte metabolism and adipogenesis. *J Cell Mol Med* 2011; 15: 1927–1940.
4. Schulteis G, Yackey M, Risbrough V, Koob GF. Anxiogenic-like effects of spontaneous and naloxone-precipitated opiate withdrawal in the elevated plus-maze. *Pharmacol Biochem Behav*. 1998;60(3):727-31.
5. Li T, Hou Y, Cao W, Yan CX, Chen T, Li SB. Naloxone-precipitated withdrawal enhances ERK phosphorylation in prefrontal

association cortex and accumbens nucleus of morphine-dependent mice. *Neurosci Lett.* 2010;468(3):348-52.

6. Vicennati V, Genghini S, and Iasio DR. Circulating obestatin levels and the ghrelin/obestatin ratio in obese women. *European Journal of Endocrinology* 2007; 157: 295–301.
7. Taskin MI, Bulbul E, Adali E, Hismiogullari AA, and Inceboz U. Circulating levels of obestatin and co-peptin in obese and nonobese women with polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol.* 2015 Jun;189:19-23.
8. Yildiz G, Yucel A, Nayan V et al. Evaluation of effects of diet on serum obestatin levels in over-weight patients with polycystic ovary syndrome. *Journal of obesity and metabolic research.* 2014;1(4):230-237.
9. Dixit, VD, Yang, H, Cooper-Jenkins, A. Reduction of T cell-derived ghrelin enhances proinflammatory cytokine expression: implications for age-associated increases in inflammation. *Blood* 2009; 113: 5202–5205
10. Kellokoski, E, Kunnari, A, Jokela, M. Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. *Metabolism* 2009; 58: 1572–1580.
11. Matthews, DR, Hosker, JP, Rudenski, AS. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412–419.
12. Kadoglou, NP, Sailer, N, Moutzouoglou, A. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. *Exp Clin Endocrinol Diabetes* 2010; 118: 75–80.
13. Li, ZF, Guo, ZF, Yang, SG. Circulating ghrelin and ghrelin to obestatin ratio are low in patients with untreated mild-to-moderate hypertension. *Regul Pept* 2010; 165: 206–209